News|Articles|November 16, 2026

Cretostimogene Grenadenorepvec Improves RFS in Intermediate-Risk and High-Grade Ta NMIBC

Author(s)Ryan Kret
Fact checked by: Chris Ryan
Listen
0:00 / 0:00

Key Takeaways

  • A randomized phase 3 design enrolled 367 post-TURBT patients across defined intermediate-risk presentations while excluding CIS, high-grade T1, muscle-invasive/metastatic disease, and prior Ad5-based therapy.
  • Efficacy was driven by a 68% reduction in recurrence/death versus surveillance (HR 0.32; 95% CI 0.23–0.45), meeting the primary RFS end point at 17 months median follow-up.
SHOW MORE

Adjuvant intravesical cretostimogene grenadenorepvec improved recurrence-free survival (RFS) vs surveillance after complete resection in patients with intermediate-risk non–muscle-invasive bladder cancer (NMIBC) and high-grade Ta tumors measuring 3 cm or less, meeting the primary end point of the phase 3 PIVOT-006 trial (NCT06111235).1

Findings announced by CG Oncology showed that, as of the data cutoff of October 26, 2026, and at the median follow-up was 17 months, cretostimogene grenadenorepvec reduced the risk of recurrence or death by 68% compared with surveillance (HR, 0.32; 95% CI, 0.23-0.45; P < .0001). In an announcement of the study’s topline data, the company also noted that no grade 3 or higher treatment-related adverse effects (TRAEs) or treatment-related discontinuations were reported.

“Today’s results highlight our differentiated clinical approach, aimed at exploring cretostimogene across the broad NMIBC spectrum and build upon our robust body of clinical evidence including what we believe to be the best-in-disease safety and tolerability data reported,“ Vijay Kasturi, MD, chief medical officer of CG Oncology, stated in a news release. “For patients with intermediate-risk and high-grade Ta NMIBC, reducing recurrence is a meaningful clinical objective because recurrence can bring additional invasive procedures and continued disease burden. The significant improvement in RFS observed in PIVOT-006 across both [patients with] high-grade and low-grade [disease] underscores the promise of cretostimogene as an important potential new treatment option following tumor resection. These data give us the opportunity to change clinical practice and help more people remain cancer-free longer while reducing the burden of their disease.”

Full data from PIVOT-006 will be presented at the Society of Urologic Oncology Annual Meeting on December 2, 2026.

In 2025, CG Oncology initiated submission of a rolling biologics license application to the FDA seeking the approval of cretostimogene grenadenorepvec for the treatment of patients with high-risk, BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without Ta/T1 disease, based on data from cohort C of the single-arm, phase 3 BOND-003 trial (NCT04452591).2 The company is working to complete a BLA filing for an intermediate-risk and high-grade Ta NMIBC indication in 2027.1

“Based on FDA feedback, we plan to broaden our initial BLA submission in BCG-unresponsive NMIBC, which was focused on patients with CIS with or without papillary tumors, to also include patients with high-grade papillary-only disease,” Arthur Kuan, chairman, president, and chief executive officer of CG Oncology, stated in a news release. “Together, these populations represent the full range of [patients with] BCG-unresponsive [disease], and our goal is a label that reflects that. To incorporate the additional data, we now expect to complete the submission before the end of March 2027. All BLA-enabling manufacturing activities supporting both regulatory filings have been completed. Ultimately, this strategy reflects our commitment to meaningfully improve the lives of as many bladder cancer patients as possible.”

What is the mechanism of action of cretostimogene grenadenorepvec?

Cretostimogene grenadenorepvec is an investigational, engineered oncolytic adenovirus administered intravesically. It works through 2 mechanisms: selective viral replication that destroys tumor cells and activation of an antitumor immune response.3

How was the PIVOT-006 trial designed?

The study enrolled 367 adult patients with pathologically confirmed disease, all of whom had undergone transurethral resection of bladder tumor (TURBT) that cleared visible tumor no more than 90 days before randomization.4 Qualifying presentations were low-grade Ta tumors that recurred within 12 months, were solitary and larger than 3 cm, or were multifocal; low-grade T1 tumors; and primary, solitary high-grade Ta tumors no larger than 3 cm.

Key exclusions included high-risk features such as CIS or high-grade T1 disease, muscle-invasive or metastatic bladder cancer, and any prior human adenovirus serotype 5–based therapy.

After TURBT, patients were randomly assigned 1:1 to receive adjuvant cretostimogene grenadenorepvec or undergo surveillance. In the experimental arm, induction consisted of intravesical cretostimogene grenadenorepvec at 1 × 1012 viral particles/mL once weekly for 6 weeks, after which patients without recurrence moved on to maintenance. Maintenance comprised 3 weekly doses at months 3 and 6, followed by single doses at months 9 and 12.

Crossover to cretostimogene grenadenorepvec was allowed for patients in the surveillance arm who developed an intermediate-risk recurrence.

RFS served as the primary end point; secondary end points included RFS rates at 6, 12, and 24 months, as well as safety.

References

  1. PIVOT-006 phase 3 registrational trial demonstrates unprecedented improvement in recurrence-free survival (RFS) for intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC). News release. CG Oncology. November 16, 2026. Accessed November 16, 2026. https://www.globenewswire.com/news-release/2026/11/16/3403439/0/en/pivot-006-phase-3-registrational-trial-demonstrates-unprecedented-improvement-in-recurrence-free-survival-rfs-for-intermediate-risk-and-high-grade-ta-non-muscle-invasive-bladder-ca.html
  2. CG Oncology reports third quarter 2025 financial results and provides business updates. News release. CG Oncology, Inc. November 14, 2025. Accessed November 16, 2026. https://www.sec.gov/Archives/edgar/data/1991792/000119312525281672/ck0001991792-ex99_1.htm
  3. CG Oncology, Inc. Annual report on Form 10-K for the fiscal year ended December 31, 2025. Accessed November 16, 2026. https://ir.cgoncology.com/node/8196/html
  4. A study of adjuvant cretostimogene grenadenorepvec for treatment of intermediate risk NMIBC following TURBT (PIVOT-006). ClinicalTrials.gov. Updated July 1, 2026. Accessed November 16, 2026. https://clinicaltrials.gov/study/NCT06111235

Related to this article